1. Once India’s richest man, Sun Pharma head Dilip Shanghvi loses $14.1 bln in 2 years on US FDA drug woes

Once India’s richest man, Sun Pharma head Dilip Shanghvi loses $14.1 bln in 2 years on US FDA drug woes

Dilip Shanghvi’s shrinking fortune has become one of the most visible casualties of the troubles hitting India’s generic drug industry.

By: | Updated: June 7, 2017 11:47 AM
dilip Sanghvi, Sun Phrma, India’s richest person, U.S. Food and Drug Administration, Pharmaceutical Industries Ltd, Pharma’s largest market Dilip Shanghvi, who was once India’s richest man, has lost more than half his fortune, as US FDA woes have hit shares of his Sun Pharma hard over the last two years. (Image: Reuters)

Dilip Shanghvi’s shrinking fortune has become one of the most visible casualties of the troubles hitting India’s generic drug industry. Once India’s richest person, he recently slipped to No. 6 with his fortune dropping $14.1 billion from its peak of about two years ago. The founder and head of Sun Pharmaceutical Industries Ltd. has seen his net worth fall to $11.1 billion on the Bloomberg Billionaires Index, as shares of India’s largest drug maker tumbled 57 percent from its all-time high in April 2015. The drop intensified last month after a quarterly earnings report showed the twin headwinds from out of the U.S. that have been hitting India’s drug makers the last few years only worsened for Sun. India’s sprawling generic drug industry has come under increased scrutiny as the U.S. Food and Drug Administration steps up inspections of approved overseas manufacturers, the largest concentration of which are in the Asian nation.

The FDA also authorized a record number of new generic drugs last year, unleashing a flood of competition that has combined with consolidation among the biggest U.S. buyers of generics to force down prices in the world’s largest drug market. Meanwhile, a key Sun Pharma plant in the Western Indian state of Gujarat was caught up in the regulator’s inspection blitz with the FDA barring new product approvals from the facility until its concerns are addressed. After nearly a year of remediation, the Halol facility was reinspected last year, resulting in a new list of issues.

You may also like to watch:

The company said recently it now assumes there will be no new approvals from the plant this year. The U.S. is Sun Pharma’s largest market. A Sun Pharma spokesman declined to comment on the company’s share price and Shanghvi’s net worth. The sanctioned plant and competition combined last quarter to shrink sales, and prompted Shanghvi to warn in a conference call that the pressure shows no sign of letting up, and could drive Sun’s first annual sales decline in eight years. “There is a new normal that is getting established,” he said.

  1. No Comments.

Go to Top